Optimizing the aldosterone-to-renin ratio cut-off for screening primary aldosteronism based on cardiovascular risk: a collaborative study

References

• Stowasser M, Gordon RD. Primary aldosteronism: changing definitions and new concepts of physiology and pathophysiology both inside and outside the kidney. Physiol Rev. 2016;96(4):1327–8. doi:10.1152/physrev.00026.2015.
   PubMed Web of Science ®Google Scholar
• Monticone S, D’Ascenzo F, Moretti C, Williams TA, Veglio F, Gaita F, Mulatero P. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2018;6(1):41–50. doi:10.1016/S2213-8587(17)30319-4.
   PubMed Web of Science ®Google Scholar
• Hundemer GL, Curhan GC, Yozamp N, Wang M, Vaidya A. Cardiometabolic outcomes and mortality in medically treated primary aldosteronism: a retrospective cohort study. Lancet Diabetes Endocrinol. 2018;6(1):51–59. doi:10.1016/S2213-8587(17)30367-4.
   PubMed Web of Science ®Google Scholar
• Xu Z, Yang J, Hu J, Song Y, He W, Luo T, Cheng Q, Ma L, Luo R, Fuller PJ, et al. Primary aldosteronism in patients in China with Recently detected hypertension. J Am Coll Cardiol. 2020;75(16):1913–22. doi:10.1016/j.jacc.2020.02.052.
   PubMed Web of Science ®Google Scholar
• Funder JW, Carey RM, Mantero F, Murad MH, Reincke M, Shibata H, Stowasser M, Young WF. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101(5):1889–916. doi:10.1210/jc.2015-4061.
   PubMed Web of Science ®Google Scholar
• Mulatero P, Monticone S, Deinum J, Amar L, Prejbisz A, Zennaro M-C, Beuschlein F, Rossi GP, Nishikawa T, Morganti A, et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the working group on endocrine hypertension of the European society of hypertension. J Hypertens. 2020;38(10):1919–28. doi:10.1097/HJH.0000000000002510.
   PubMed Web of Science ®Google Scholar
• Naruse M, Katabami T, Shibata H, Sone M, Takahashi K, Tanabe A, Izawa S, Ichijo T, Otsuki M, Omura M, et al. Japan Endocrine Society clinical practice guideline for the diagnosis and management of primary aldosteronism 2021. Endocr J. 2022;69(4):327–59. doi:10.1507/endocrj.EJ21-0508.
   PubMed Web of Science ®Google Scholar
• Hung A, Ahmed S, Gupta A, Davis A, Kline GA, Leung AA, Ruzicka M, Hiremath S, Hundemer GL. Performance of the aldosterone to renin ratio as a screening test for primary aldosteronism. J Clin Endocrinol Metab. 2021;106(8):2423–35. doi:10.1210/clinem/dgab348.
   PubMed Web of Science ®Google Scholar
• Leung AA, Symonds CJ, Hundemer GL, Ronksley PE, Lorenzetti DL, Pasieka JL, Harvey A, Kline GA. Performance of confirmatory tests for diagnosing primary aldosteronism: a systematic review and meta-analysis. Hypertension. 2022;79(8):1835–44. doi:10.1161/HYPERTENSIONAHA.122.19377.
   PubMed Web of Science ®Google Scholar
• Satoh M, Kikuya M, Ohkubo T, Mori T, Metoki H, Hara A, Utsugi MT, Hashimoto T, Hirose T, Obara T, et al. Aldosterone-to-renin ratio as a predictor of stroke under conditions of high sodium intake: the ohasama study. Am J Hypertens. 2012;25(7):777–83. doi:10.1038/ajh.2012.33.
   PubMed Web of Science ®Google Scholar
• Kisaka T, Ozono R, Ishida T, Higashi Y, Oshima T, Kihara Y. Association of elevated plasma aldosterone-to-renin ratio with future cardiovascular events in patients with essential hypertension. J Hypertens. 2012;30(12):2322–30. doi:10.1097/HJH.0b013e328359862d.
   PubMed Web of Science ®Google Scholar
• Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham offspring study. Design and preliminary data. Prev Med. 1975;4(4):518–25. doi:10.1016/0091-7435(75)90037-7.
   PubMed Web of Science ®Google Scholar
• Vasan RS, Evans JC, Larson MG, Wilson PWF, Meigs JB, Rifai N, Benjamin EJ, Levy D. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med. 2004;351(1):33–41. doi:10.1056/NEJMoa033263.
   PubMed Web of Science ®Google Scholar
• Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. N Engl J Med. 2006;355(25):2631–9. doi:10.1056/NEJMoa055373.
   PubMed Web of Science ®Google Scholar
• Parikh NI, Gona P, Larson MG, Wang TJ, Newton-Cheh C, Levy D, Benjamin EJ, Kannel WB, Vasan RS. Plasma renin and risk of cardiovascular disease and mortality: the Framingham heart study. Eur Heart J. 2007;28(21):2644–52. doi:10.1093/eurheartj/ehm399.
   PubMed Web of Science ®Google Scholar
• Ingelsson E, Pencina MJ, Tofler GH, Benjamin EJ, Lanier KJ, Jacques PF, Fox CS, Meigs JB, Levy D, Larson MG, et al. Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham offspring study. Circulation. 2007;116(9):984–92. doi:10.1161/CIRCULATIONAHA.107.708537.
   PubMed Web of Science ®Google Scholar
• Morshedi-Meibodi A, Evans JC, Levy D, Larson MG, Vasan RS. Clinical correlates and prognostic significance of exercise-induced ventricular premature beats in the community: the Framingham heart study. Circulation. 2004;109(20):2417–22. doi:10.1161/01.CIR.0000129762.41889.41.
   PubMed Web of Science ®Google Scholar
• Optimizing the aldosterone-to-renin ratio cut-off for screening primary aldosteronism based on cardiovascular risk: a collaborative study-supplemental materials. Figshare. 2023. 10.6084/m9.figshare.23601024.v6
   Google Scholar
• Wang K, Hu J, Yang J, Song Y, Fuller PJ, Hashimura H, He W, Feng Z, Cheng Q, Du Z, et al. Development and validation of criteria for sparing confirmatory tests in diagnosing primary aldosteronism. J Clin Endocrinol Metab. 2020;105(7):e2449–e2456. doi:10.1210/clinem/dgaa282.
   Web of Science ®Google Scholar
• Song Y, Yang S, He W, Hu J, Cheng Q, Wang Y, Luo T, Ma L, Zhen Q, Zhang S, et al. Confirmatory tests for the diagnosis of primary aldosteronism: a prospective diagnostic accuracy study. Hypertension. 2018;71(1):118–24. doi:10.1161/HYPERTENSIONAHA.117.10197.
   PubMed Web of Science ®Google Scholar
• Hu J, Shen H, Huo P, Yang J, Fuller PJ, Wang K, Yang Y, Ma L, Cheng Q, Gong L, et al. Heightened Cardiovascular Risk in Hypertension Associated With Renin-Independent Aldosteronism Versus Renin-Dependent Aldosteronism: A Collaborative Study. J Am Heart Assoc. 2021;10(24):e023082. doi:10.1161/JAHA.121.023082.
   PubMed Web of Science ®Google Scholar
• Ma L, Song Y, Mei M, He, W, Hu, J, Cheng, Q, Tang, Z, Luo, T, Wang, Y, Zhen, Q, et al. Age-related cutoffs of plasma aldosterone/renin concentration for primary aldosteronism screening. Int J Endocrinol 2018; 8647026.
   PubMed Web of Science ®Google Scholar
• Liu B, Hu J, Song Y, He W, Cheng Q, Wang Z, Feng Z, Du Z, Xu Z, Yang J, et al. Seated saline suppression test is comparable with captopril challenge test for the diagnosis of primary aldosteronism: a prospective study. Endocr Pract. 2021;27(4):326–33. doi:10.1016/j.eprac.2020.10.016.
   PubMed Web of Science ®Google Scholar
• Jing Y, Hu J, Luo R, Mao Y, Luo Z, Zhang M, Yang J, Song Y, Feng Z, Wang Z, et al. Prevalence and characteristics of adrenal tumors in an unselected screening population: a cross-sectional study. Ann Intern Med. 2022;175(10):1383–91. doi:10.7326/M22-1619.
   PubMed Web of Science ®Google Scholar
• Li X, Goswami R, Yang S, Li Q. Aldosterone/direct renin concentration ratio as a screening test for primary aldosteronism: a meta-analysis. J Renin Angiotensin Aldosterone Syst. 2016;17(3):147032031665745. doi:10.1177/1470320316657450.
   Web of Science ®Google Scholar
• Li N, Huang J, Zheng B, Cai H, Liu M, Liu L. Cost-effectiveness analysis of screening for primary aldosteronism in China. Clin Endocrinol (Oxf). 2021;95(3):414–22. doi:10.1111/cen.14478.
   PubMed Web of Science ®Google Scholar
• Lubitz CC, Economopoulos KP, Sy S, Johanson C, Kunzel HE, Reincke M, Gazelle GS, Weinstein MC, Gaziano TA. Cost-effectiveness of screening for primary aldosteronism and subtype diagnosis in the resistant hypertensive patients. Circ Cardiovasc Qual Outcomes. 2015;8(6):621–30. doi:10.1161/CIRCOUTCOMES.115.002002.
   PubMed Web of Science ®Google Scholar
• Sato M, Morimoto R, Seiji K, Iwakura Y, Ono Y, Kudo M, Satoh F, Ito S, Ishibashi T, Takase K, et al. Cost-effectiveness analysis of the diagnosis and treatment of primary aldosteronism in Japan. Horm Metab Res. 2015;47(11):826–32. doi:10.1055/s-0035-1559645.
   PubMed Web of Science ®Google Scholar
• Woode ME, Wong K, Reid CM, Stowasser M, Russell G, Gwini S, Young MJ, Fuller PJ, Yang J, Chen G, et al. Cost-effectiveness of screening for primary aldosteronism in hypertensive patients in Australia: a Markov modelling analysis. J Hypertens. 2023;41(10):1615–25. doi:10.1097/HJH.0000000000003513.
   PubMed Web of Science ®Google Scholar
• Funder JW. Who and how should we screen for primary aldosteronism? Hypertension. 2023;80(12):2495–2500. doi:10.1161/HYPERTENSIONAHA.123.20536.
   PubMed Web of Science ®Google Scholar